Every 8-K that CryoPort, Inc. (CYRX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow CYRX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CYRX filings page.
Cryoport, Inc. reported Q2 2026 revenue of $48,971 thousand, up 8% year-over-year, and first-half revenue of $96,769 thousand, up 12%. Life Sciences Services grew 15% to $27,969 thousand, driven by 13% growth in BioLogistics Solutions and 25% growth in BioStorage/BioServices, while Life Sciences Products was flat at $21,002 thousand.
Cell and gene therapy activity remained strong, with $9.4 million in commercial CGT revenue, $13.4 million from supporting CGT clinical trials, and a record 779 supported trials worldwide, including 94 in Phase 3. GAAP loss from continuing operations narrowed to $8,255 thousand from $12,014 thousand a year earlier, and adjusted EBITDA from continuing operations turned positive at $375 thousand versus a prior loss of $914 thousand.
As of June 30, 2026, Cryoport held $269,267 thousand in cash and cash equivalents and $127,426 thousand in short-term investments, against total liabilities of $265,505 thousand and stockholders’ equity of $490,699 thousand, including a current portion of convertible senior notes of $185,687 thousand.
Cryoport, Inc. reported results from its 2026 Annual Meeting of Stockholders. Shareholders elected six directors, with votes for each nominee ranging from 38.9 million to 40.9 million, with additional broker non-votes recorded.
Stockholders ratified Deloitte & Touche LLP as independent auditor with 47,014,962 votes for. They approved executive compensation on an advisory basis with 39,533,693 votes for, and approved an amendment to the 2018 Omnibus Equity Incentive Plan to increase authorized shares, with 30,110,893 votes for and 12,591,758 against.
Cryoport, Inc. reported a strong start to 2026, with first-quarter revenue of $47.8 million, up 16% year-over-year. Life Sciences Services revenue rose to $26.9 million (up 18%), and Life Sciences Products reached $20.9 million (up 15%), driven by demand for cryogenic systems and integrated logistics.
Revenue supporting commercial cell and gene therapies grew 26% to $9.1 million, while clinical trial support revenue increased 18% to $12.9 million. The company supported 766 clinical trials as of March 31, 2026, including 91 in Phase 3 and 21 commercial therapies.
Despite growth, Cryoport posted a loss from continuing operations of $9.4 million and a net loss of $10.5 million, or -$0.25 per share, though adjusted EBITDA from continuing operations improved to -$0.6 million from -$2.8 million. Cash and cash equivalents were $272.9 million with $130.7 million in short-term investments, and full-year 2026 revenue guidance was raised to $192–$196 million.
Cryoport, Inc. reported solid growth for 2025 with improving profitability trends. Full-year revenue reached $176.2 million, exceeding the high end of prior guidance and rising 12% year-over-year, while fourth-quarter revenue grew 10% to $45.5 million. Life Sciences Services revenue increased 18% to $96.5 million and Life Sciences Products revenue grew 7% to $79.7 million. Gross margin for 2025 was 47%, supported by cost reduction initiatives and a $12 million year-over-year improvement in adjusted EBITDA from continuing operations to a loss of $5.8 million.
Cryoport’s position in cell and gene therapy strengthened, with revenue from commercial CGT support up 29% to $33.4 million and clinical trial support revenue up 14% to $47.1 million. The company backed 760 global clinical trials at year-end, including 86 in Phase 3, and supported 20 commercial therapies. After the CRYOPDP divestiture and strategic partnership with DHL, cash and cash equivalents rose to $250.5 million and short-term investments to $160.7 million. For 2026, Cryoport issued revenue guidance of $190 million to $194 million.
Cryoport, Inc. furnished an 8-K announcing it issued a press release with financial results for the third quarter ended September 30, 2025. The press release is attached as Exhibit 99.1. The company states this information is being furnished and is not deemed filed under Section 18 of the Exchange Act. The filing was signed by Chief Financial Officer Robert Stefanovich on November 4, 2025.